How do correlates of protection (CoPs) for AMP1 differ between neutralization-dependent and Fc-mediated mechanisms?
Neutralization-dependent CoPs: Link serum antibody concentration to IC80/IC50 values against circulating strains.
Fc-mediated CoPs: Measure antibody-dependent cellular cytotoxicity (ADCC) activity against infected cells.
Example findings from AMP trials :
| CoP Type | Threshold for Protection |
|---|---|
| Neutralization (IC80) | ≥ 80% inhibition |
| ADCC activity | ≥ 50% target cell lysis |
How should researchers resolve contradictions in AMP1 efficacy data across viral clades?
What methodologies optimize AMP1’s manufacturability for clinical translation?
Use deep sequencing to track envelope (Env) evolution in breakthrough infections .
Prioritize antibodies with breadth across tier 2/3 viruses in preclinical screens .
Standardize neutralization assays using WHO reference panels.
Include internal controls for Fc function assays (e.g., CD16-binding kinetics) .
Conduct post hoc analyses to identify subgroups with partial efficacy (e.g., high-risk populations).
Compare AMP1’s neutralization breadth to next-generation bnAbs (e.g., CAP256-VRC26) .
| Parameter | 10 mg/kg Group | 30 mg/kg Group |
|---|---|---|
| Median Serum Half-life | 21 days | 28 days |
| Prevention Efficacy (PE) | 25% | 40% |
| IC80 Coverage | 30% of strains | 65% of strains |